Skip to main content

Perceptive Advisors — Portfolio, Page 5

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

224
Companies
$26.6B
Total invested
$135.1M
Avg. check
16
Industries
Biotechnology 21Health Care 15Therapeutics 15Pharmaceutical 9Medical 8Life Science 5+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 97120 of 224
Crescent Biopharma
December 2025

Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.

Biotechnology · Rockville$185.0M Post-IPO Equity
SpringWorks Therapeutics
December 2023

SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.

Biopharma · Stamford$275.0M Post-IPO Equity
Athira Pharma
December 2025

Athira Pharma is a clinical stage drug development company that specializes in biotechnology and pharmaceutical.

Biotechnology · Seattle$90.0M Post-IPO Equity
Yarrow
December 2025

Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.

Business Intelligence · New York$200.0M Venture - Series Unknown
Mythic Therapeutics
December 2021

Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics.

Biotechnology · Waltham$103.0M Series B
Contineum Therapeutics
December 2025

Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.

Biotechnology · San Diego$99.2M Post-IPO Equity
Fulcrum Therapeutics
December 2025

Fulcrum Therapeutics is a biotechnology company that focuses on identifying and treating rare genetic diseases at their root cause.

Biotechnology · Cambridge$175.0M Post-IPO Equity
Escient Pharmaceuticals
November 2022

Escient Pharmaceuticals is a privately-held biotechnology company focusing on the advancement of G Protein-Coupled Receptor targeted drugs.

Biotechnology · San Diego$120.0M Series C
Thrive Earlier Detection
January 2023

Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.

Biotechnology · CambridgeVenture - Series Unknown
Sermonix Pharmaceuticals
November 2021

Sermonix Pharmaceuticals is an Ohio LLC specialty pharmaceutical.

Biopharma · Columbus$40.0M Series A
Alector
November 2024

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.

Biotechnology · San Francisco$50.0M Post-IPO Debt
TELA Bio
November 2025

TELA Bio is a life science company that specializes in soft tissue reconstruction.

Biotechnology · Malvern$60.0M Post-IPO Debt
Beta Bionics
November 2024

Beta Bionics is a biotechnology company that provides software to reduce the burden of diabetes care.

Biotechnology · Irvine$60.0M Series E
Cogent Biosciences
November 2025

Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.

Biotechnology · Waltham$200.0M Post-IPO Debt
Confo Therapeutics
October 2025

Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need.

Biotechnology · Brussels$1.2M Grant
Affinia Therapeutics
October 2025

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.

Biotechnology · Waltham$40.0M Series C
TORL BioTherapeutics
October 2025

TORL BioTherapeutics is a clinical-stage biopharmaceutical business.

Biopharma · Culver City$96.0M Series C
Science 37
October 2021

Science 37 is a clinical research company that facilitates universal participation in clinical trials for patients and providers.

Biotechnology · Culver City$200.0M Post-IPO Equity
Cidara Therapeutics
October 2025

Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.

Biotechnology · San Diego$339.0M Grant
Axonis Therapeutics
October 2024

Axonis Therapeutics is a neuro-focused biotechnology company that focuses on the development of novel neuromedicines.

Biotechnology · Boston$115.0M Series A
Nurix Therapeutics
October 2025

Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.

Biotechnology · San Francisco$250.0M Post-IPO Equity
Rapt Therapeutics
October 2025

Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.

Biotechnology · South San Francisco$250.0M Post-IPO Equity
Adagio Medical
October 2025

Adagio Medical is engaged in the research and development of treatments for cardiovascular diseases.

Health Care · Laguna Hills$19.0M Post-IPO Equity
Cerevel Therapeutics
October 2023

Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.

Biotechnology · Boston$450.0M Post-IPO Equity

Where Perceptive Advisors invests

Biotechnology21
Health Care15
Therapeutics15
Pharmaceutical9
Medical8
Life Science5

About Perceptive Advisors's portfolio

How many companies has Perceptive Advisors invested in?

Perceptive Advisors has invested in 224 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Perceptive Advisors invest in?

Perceptive Advisors's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 16 different industry categories.

What is Perceptive Advisors's largest investment?

Among tracked funding rounds, Cerevel Therapeutics received $450.0M in a Post-IPO Equity round. Perceptive Advisors's total known invested capital is $26.6B.

What is the average investment size for Perceptive Advisors?

Perceptive Advisors's average investment size is $135.1M across its portfolio of 224 companies.

What are Perceptive Advisors's most recent investments?

Recent Perceptive Advisors portfolio additions include Crescent Biopharma, SpringWorks Therapeutics, Athira Pharma, Yarrow, Mythic Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 224 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →